Metraipolis › archive › dc_15cfd33d5bb0

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study — Europe PMC PMID:40973475

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40973475
DOI
10.1093/oncolo/oyaf286
License (as archived)
solo-consultazione
Archived
2026-11-08T21:19:15.386Z
SHA-256 of the archived text
653d059e0876aff9ecb4e46284c05222f0c8225159cc0a1f2d206ced513134c2
Stable URL of this page
https://metraipolis.com/documento/dc_15cfd33d5bb0

How to cite

First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study — Europe PMC PMID:40973475 — Europe PMC (en), https://europepmc.org/article/MED/40973475 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_15cfd33d5bb0 (Metraipolis archive dc_15cfd33d5bb0, sha256 653d059e0876aff9ecb4e46284c05222f0c8225159cc0a1f2d206ced513134c2)
BibTeX
@misc{dc15cfd33d5bb0,
  title = {First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study — Europe PMC PMID:40973475},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40973475},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_15cfd33d5bb0; sha256 653d059e0876aff9ecb4e46284c05222f0c8225159cc0a1f2d206ced513134c2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40973475. Agents can read the archived copy with the MCP tool read_document.